Lipase 24,000 UNT / amylase 120,000 UNT / protease 76,000 UNT Delayed Release Oral Capsule
RxNorm 855495
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 855495 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: lipase 24,000 UNT / amylase 120,000 UNT / protease 76,000 UNT Delayed Release Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Amylase 120000 UNT / lipase 24000 UNT / protease 76000 UNT Delayed Release Oral Capsule
(Atom ID: 12333068)
SYPrescribable
Synonym (SY):
Amylase 120,000 UNT / lipase 24,000 UNT / protease 76,000 UNT Delayed Release Oral Capsule
(Atom ID: 11843128)
SYPrescribable
Synonym (SY):
Amylases 120,000 UNT / endopeptidases 76,000 UNT / lipase 24,000 UNT Delayed Release Oral Capsule
(Atom ID: 11843129)
PSNPrescribable
Prescribable Name (PSN):
Lipase 24,000 UNT / amylase 120,000 UNT / protease 76,000 UNT Delayed Release Oral Capsule
(Atom ID: 6385634)
Patient Education
Pancrelipase
Pancrelipase delayed-release capsules (Creon, Pancreaze, Pertzye, Ultresa, Zenpep) are used to improve digestion of food in children and adults who do not have enough pancreatic enzymes (substances needed to break down food so it can be digested) because they have a condition that affects the pancreas (a gland that produces several important substances including enzymes needed to digest food) such as cystic fibrosis (an inborn disease that causes the body to produce thick, sticky mucus that may clog the pancreas, the lungs, and other parts of the body), chronic pancreatitis (swelling of the pancreas that does not go away), or a blockage in the passages between the pancreas and the intestine. Pancrelipase delayed-release capsules (Creon, Pancreaze, Zenpep) are also used to improve digestion of food in infants who do not have enough pancreatic enzymes (substances needed to break down food so it can be digested) because they have cystic fibrosis or another condition that affects the pancreas. Pancrelipase delayed-release capsules (Creon) are also used to improve digestion in people who have had surgery to remove all or part of the pancreas or stomach. Pancrelipase tablets (Viokace) are used along with another medication (proton pump inhibitor; PPI) to improve digestion of foods in adults who have chronic pancreatitis or who have had surgery to remove the pancreas. Pancrelipase is in a class of medications called enzymes. Pancrelipase acts in place of the enzymes normally made by the pancreas. It works to decrease fatty bowel movements and to improve nutrition by breaking down fats, proteins, and starches from food into smaller substances that can be absorbed from the intestine.
[Learn More]
Lipase
What is it? Lipase is a compound involved in the break down of fats during digestion. It is found in many plants, animals, bacteria, and molds. Some people use lipase as a medicine.
Lipase is most commonly used for indigestion (dyspepsia), heartburn, and other gastrointestinal problems, but there is no good scientific evidence to support these uses.
Do not confuse lipase with pancreatic enzyme products. Pancreatic enzyme products contain multiple ingredients, including lipase. Some of these products are approved by the US FDA for digestion problems due to a disorder of the pancreas (pancreatic insufficiency).
[Learn More]
* Please review the disclaimer below.
